162 related articles for article (PubMed ID: 30368729)
1. Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.
Chmelarova M; Baranova I; Ruszova E; Laco J; Hrochova K; Dvorakova E; Palicka V
Pathol Oncol Res; 2019 Oct; 25(4):1457-1465. PubMed ID: 30368729
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.
Baranova I; Kovarikova H; Laco J; Dvorak O; Sedlakova I; Palicka V; Chmelarova M
Cancer Biomark; 2018; 23(1):125-133. PubMed ID: 29991130
[TBL] [Abstract][Full Text] [Related]
4. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
Pradjatmo H
Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
6. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
7. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene.
Horiuchi A; Hayashi T; Kikuchi N; Hayashi A; Fuseya C; Shiozawa T; Konishi I
Int J Cancer; 2012 Oct; 131(8):1755-67. PubMed ID: 22287060
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer.
Bubancova I; Kovarikova H; Laco J; Ruszova E; Dvorak O; Palicka V; Chmelarova M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241454
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
11. Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Vaclavikova R; Klajic J; Brynychova V; Elsnerova K; Alnaes GIG; Tost J; Kristensen VN; Rob L; Kodet R; Skapa P; Mrhalova M; Soucek P
Oncol Rep; 2019 Aug; 42(2):763-774. PubMed ID: 31173253
[TBL] [Abstract][Full Text] [Related]
12. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
13. Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma.
Sheng Y; Wang H; Liu D; Zhang C; Deng Y; Yang F; Zhang T; Zhang C
Gynecol Oncol; 2016 Jan; 140(1):145-51. PubMed ID: 26597461
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
15. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
16. The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer.
Meng X; Lu P; Chu Z; Fan Q
Oncotarget; 2016 Jan; 7(2):2105-12. PubMed ID: 26556855
[TBL] [Abstract][Full Text] [Related]
17. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer.
Choi PW; Bahrampour A; Ng SK; Liu SK; Qiu W; Xie F; Kuo WP; Kwong J; Hales KH; Hales DB; Wong KK; Norwitz ER; Chow CK; Berkowitz RS; Ng SW
Sci Rep; 2020 Nov; 10(1):20071. PubMed ID: 33208870
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.
Rinck-Junior JA; Oliveira C; Lourenço GJ; Sagarra RA; Derchain SF; Segalla JG; Lima CS
J Cancer Res Clin Oncol; 2015 Jan; 141(1):69-73. PubMed ID: 25092217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]